Navigation Links
NYSE Amex Accepts Interleukin Genetics' Plan to Meet Continued Listing Standards
Date:5/14/2009

WALTHAM, Mass., May 14 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that the Corporate Compliance Staff of the NYSE Amex LLC (the "Exchange") has accepted the company's plan to meet the Exchange's continued listing standards, and has granted the company an extension to become compliant, through December 31, 2009. As a result of the Staff extension, the company was not required to attend a hearing before the Listing Qualifications Panel, as discussed in the company's press release dated March 30, 2009.

"We are pleased with the decision by the Exchange to continue our listing and look forward to meeting the business goals established by the company in our plan," said Lewis H. Bender, CEO, Interleukin Genetics. "The decision provides us with a reasonable timeline to achieve our objectives and become compliant with the listing standards. We look to execute on our business strategy and establish our leadership in the personalized health industry."

The company will be subject to periodic review by the Exchange staff during the extension period. In addition, while the company expects to comply with all applicable requirements for continued listing on the Exchange by December 31, 2009, there can be no assurance that the company will be able to do so.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI), is a genetics-focused personalized health company that develops preventative consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventative and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
2. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
3. American Stock Exchange Accepts Encisions Plan to Regain Compliance
4. Governor Rendell Accepts National Health Care Reform Pioneer Award
5. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
6. Lieutenant Governor Catherine Baker Knoll Accepts Women in Government Presidential Leadership Award
7. ev3 Inc. Accepts Resignation of Dr. John Simpson
8. Mike Huckabee Accepts Values Voter Presidential Debate
9. AMEX Accepts Lorus Plan to Meet AMEXs Continued Listing Standards
10. Partnering With MyPyramid: NUTRIKIDS Accepts the Challenge to Help Families Step Up to Healthier Living
11. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... NJ (PRWEB) , ... August 16, 2017 , ... With low back pain afflicting 8 ... know what causes its kissing cousin – upper back pain. But this equally vexing condition ... treatment options, according to Kaixuan Liu, MD, PhD , founder and president of Atlantic ...
(Date:8/16/2017)... ... 2017 , ... “Mom, God's Got This: Jamie's Story” is the creation of published author, Karen ... has an insatiable appetite for God’s Word. , “I froze between the half walls, shelves ... packages of oatmeal. I have one to this day on proud display in my dining ...
(Date:8/15/2017)... Buffalo, NY (PRWEB) , ... August 15, 2017 , ... ... as maintenance treatment for multiple myeloma has been completed, with the team’s findings now ... Philip L. McCarthy, MD , Director of the Blood and Marrow Transplant Program at ...
(Date:8/15/2017)... MD (PRWEB) , ... August 15, 2017 , ... ... from BB&T. Horizon Goodwill CEO, John McCain said, “We are overwhelmed with gratitude ... and create opportunities for people who need assistance to both get a job ...
(Date:8/15/2017)... ... 15, 2017 , ... The V Foundation for Cancer Research, ... Foundation Wine Celebration raised nearly $9 million for cancer research during a full ... donations to support the study of BRCA mutation research in laboratories and clinics ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... Colo. , July 26, 2017 E.I. ... Guttridge and the Bimini SharkLab to custom design the worlds ... images of sharks in their native habitat. In preparation ... Discovery Channel,s Shark Week, Dr. Guttridge approached EIMI ... take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... 2017 The Galien Foundation announced today ... USA Award Nominees. Counted among the global health ... outstanding biomedical and technology product achievement that improves the human ... each candidate must be U.S. Food and Drug Administration (FDA) ... tremendous potential to impact human health. Sales data are not ...
(Date:7/24/2017)... -- IBM (NYSE: IBM ) has been recognized as ... (SSA) for the fourth year in a row. 1 ... in the Leaders quadrant have the highest scores for their ... the Leaders quadrant has the market share, credibility, and marketing ... technologies. These vendors demonstrate a clear understanding of market needs; ...
Breaking Medicine Technology: